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ABSTRACT 
Objective To prospectively evaluate the association between autoimmunity to autonomic nervous 
structures and autonomic neuropathy in type 1 diabetes, in relation to clinical variables. 
Research Design and Methods A cohort of 112 patients with type 1 diabetes was prospectively 
followed from adolescence (T0) to approximately four (T4) and sixteen (T16) years later. Standard 
cardiovascular (CV) tests, neurological examination were performed and related to the presence of 
circulating antibodies (Ab) to autonomic nervous structures, detected at T0 and T4. Quality of life 
was assessed by a diabetes-specific questionnaire. 
Results Sixty-six patients (59%) of the cohort were re-examined at T16 (age 31.4 ± 2, disease 
duration 23.4 ± 3.7 years). Nineteen had circulating Ab to autonomic structures. Prevalence of 
abnormal tests and autonomic symptoms were higher in Ab-positive (68% and 26%, respectively) 
than Ab-negative patients (32% and 4%) (p < 0.05). Among Ab-positive patients, the relative risk 
of having at least one altered CV test was 5.8 [95% CI 1.55-21.33], and an altered DB test (< 15 
beats per minute) was 14.7 [2.48-86.46]. Previous glycemic control was the only other predictor 
(RR 1.06 [1.002-1.13] per mmol/mol HbA1c increase). Presence of Ab carried over a 68% 
probability of developing an altered CV test; absence of Ab carried a 91% probability of not having 
an altered DB test, and an 89% probability of not having an altered Valsalva ratio. Autonomic 
neuropathy was independently associated with worse quality of life. 
Conclusions Circulating Ab to autonomic structures are associated with the development of 
autonomic dysfunction in young diabetic patients independently of glycaemic control. 
 
Keywords: Type 1 diabetes, diabetic autonomic neuropathy, cardiovascular tests, nervous tissue 
autoantibodies, quality of life. 
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Neuropathy is a chronic complication that includes a number of distinct syndromes and 
autonomic dysfunctions and contributes to increase morbidity and mortality in the diabetic 
population. In particular, cardiovascular autonomic neuropathy (CAN) is an independent risk factor 
for mortality in type 1 diabetes and is associated with poor prognosis and poor quality of life (1-3). 
Cardiovascular autonomic regulation rests upon a balance between sympathetic and 
parasympathetic innervation of the heart and blood vessels, controlling heart rate and vascular 
dynamics. CAN encompasses several clinical manifestations, from resting tachycardia to fatal 
arrhythmia and silent myocardial infarction (4).  
The mechanisms responsible for altered neural function in diabetes are not fully understood 
and it is assumed that multiple, mutually perpetuating, pathogenic mechanisms may concur. These 
include dysmetabolic injury, neurovascular insufficiency, deficiency of neurotrophic growth factors 
and essential fatty acids, advanced glycosylation products (5, 6) and autoimmune damage. 
Independent cross-sectional and prospective (7-13) studies identified circulating autoantibodies 
(Ab) to autonomic nervous structures and hypothesized that immune determinants may be involved 
in autonomic nerve damage in type 1 diabetes. Such concept is supported by evidence that other 
forms of dysautonomia, idiopathic and paraneoplastic, can be immune mediated (14, 15). However, 
demonstration of a cause-effect relationship between Ab and diabetic autonomic neuropathy awaits 
confirmation.  
We report on a 16-year follow-up study specifically designed to prospectively examine a 
cohort of patients with type 1 diabetes and aimed at assessing whether the presence of circulating 
Ab to autonomic nervous structures is associated with increased risk and predictive value of 
developing CAN. This, in turn, would be highly suggestive of the involvement of autoimmune 
mechanisms in the pathogenesis of this complication.  
 
Research design and methods 
Subjects 
In the original design, all patients with type 1 diabetes, older than 11 and in their 
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adolescence, attending the Paediatric Diabetic Clinic of the University of Turin between 1994 and 
1997 were considered for participation in the study. Their clinical characteristics at recruitment (T0) 
and at first follow-up, approximately 4 years later (T4), were described previously (11, 12). At this 
third follow up visit, 16.5 ± 1.2 years later (T16), 66 patients out of the original cohort of 112 (59%) 
were available for re-study. One patient had died, 11 had moved, 27 could not be located and 7 
declined to participate. Their clinical characteristics are shown in Table 1. In total, 19 patients had 
circulating antibodies against autonomous nerve structures, previously detected at T0 (11) and 
persisting at T4 (12): 8 patients (12%) for vagus nerve, 10 (15%) for cervical ganglia, and 1 patient 
for both. The antibodies had been assessed by indirect immunofluorescent complement-fixation 
technique as described (8). Briefly, 5 m cryostat sections of snap-frozen cervical ganglia and 
vagus nerve, obtained from adult New Zealand white rabbit, were allowed to air dry, fixed in 
acetone and incubated with 50 l of neat test serum for 30 minutes. Slides were then washed in PBS 
and 50 l of normal human serum, as a source of complement, were added at 1:5 dilution in PBS 
for 30 minutes at 37C. After washing, 50 l of 1:20 FITC sheep anti-human C3c antiserum were 
added for a further 30 minutes at room temperature. The slides were washed, mounted in 90% 
glycerol in PBS and examined by UV microscopy by two independent observers unaware of 
clinical details. Positive staining of nerve fibres or cytoplasmic staining of ganglion cell bodies, 
were confirmed by repeated measurements using substrates from a different animal.  
Informed consent was obtained and the investigations carried out in conformity with the 
Declaration of Helsinki.   
HbA1c levels (HPLC, IFCC standardised) of the previous year (mean of 3 values) and 
previous 5 years (mean of available data) were collected to assess long-term metabolic control.  
Data on frequency of hypoglycaemic episodes over the previous 5 years were collected by 
interview, severe hypoglycaemia being defined as needing the assistance of another person.  Further 
information was acquired on the level of physical activity, occupation, schooling level, smoking 
habit and alcohol consumption. 
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Assessment of neuropathy 
A structured questionnaire, designed according to Dyck (16) was used to identify symptoms 
related to autonomic, motor and sensory function. Consumption of food and caffeine-containing 
beverages and smoking was restricted for 2 hours before testing. Heart rate was measured after 10 
minutes of supine resting. Autonomic neuropathy was assessed between 8.00 and 12.00 am, by four 
standard cardiovascular (CV) tests on an automated, computer-integrated system consisting of: 
heart rate variability upon 6 maximal breaths per minute [deep breathing (DB) test; abnormal < 15 
beats per minute, bpm, borderline 15-19 bpm]; lying to standing heart rate change (30/15 ratio; 
abnormal < 1.17, borderline 1.17-1.27); heart rate change during Valsalva manoeuvre (Valsalva 
ratio; abnormal < 1.35, borderline 1.35-1.41); postural systolic blood pressure decrease on standing 
(abnormal > 20 mmHg), as previously described (17). Age-related index values (18) were used to 
establish abnormality of the tests. 
Peripheral somatic neuropathy was assessed by clinical and neurological examination, 
including deep tendon knee and ankle reflexes and recording of vibratory perception threshold at 
the tip of the great toe, using a biothesiometer (Biomedical Instruments Co, Newbury, Ohio). The 
mean of three readings was used. 
 
Quality of life 
Diabetes related quality of life was measured in 56 patients by the DQOL questionnaire 
(19), a diabetes-specific tool designed by the DCCT Research Group and consisting of a 46-item 
multiple-choice questionnaire exploring 4 primary subscales regarding Satisfaction with Life, 
Impact, Diabetes-Related Worries and Social/Vocational Worries. Responses are along a Likert 
scale ranging from 1 to 5 (1=never, 5=all the time for impact, social and diabetes related worries 
subscales; 1=very satisfied, 5=very unsatisfied). Hence the total score ranges between 46 (highest 
quality of life) and 230 (lowest quality). The questionnaire had been translated and validated in 
Italian (20). 
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Statistical analysis 
Values for all cardiovascular tests and for the vibration threshold in the patient groups 
satisfied the hypothesis of normality, as assessed by the Kolmogorov-Smirnov goodness of fit test. 
Differences between T0, T4 and T16 data, within and between patient groups, were tested by means 
of t-tests (paired and unpaired respectively).  
Correlations between neurological and clinical parameters were analysed using the Pearson’s or 
Spearman’s correlation coefficient, depending on the variable distribution.  
Association between presence of nervous tissue autoantibodies and clinical data of autonomic 
neuropathy (dichotomised as ‘presence of at least one altered CV test’ vs ‘no altered CV tests’) was 
assessed using Fisher’s exact test or chi-square test on a 2x2 table. A multivariate logistic 
regression analysis was used to test the independent effect of the Ab presence on autonomic 
neuropathy, adjusting the model for glycaemic control, disease duration, exercise level, insulin dose 
and value at T0 of the corresponding CV test. 
The correlation between the DQOL scores, total and for its 4 different dimensions, and presence 
and severity of autonomic and somatic neuropathy was computed by means of a linear regression 
model where each of the different DQOL scores, taken one at a time, represented the dependent 
variable and presence and severity of retinopathy, presence and severity of autonomic and somatic 
neuropathy the independent ones; the model was adjusted for gender, diabetes duration and 
frequency of hypoglycaemic episodes. 
Data were analysed by the SPSS statistical package (SPSS, Chicago, ILL, USA). p values lower 
than 0.05 were considered significant. 
 
Results 
Antibody-positive and negative patients did not differ for clinical characteristics or 
prevalence of diabetic micro and macrovascular complications at T16 (Table 1). The HbA1c levels 
of the year preceding T16 (mean of 3 values) correlated with the mean HbA1c of the 5 years 
preceding T16 (r = 0.81, p < 0.01).  
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Of the 56 patients who were administered the DQOL questionnaire, 10 did not report 
hypoglycaemic episodes over the last 5 years, 11 reported less than 1 episode/month, 9 at least 
1/month, 7 reported 1/week and 19 reported more than 1/week. Severe hypoglycaemia was 
experienced at least once by 15 (27%) patients.  
 
Assessment of neuropathy at T16 and relationship with Ab to autonomic nervous structures 
Clinical neurological variables are summarised in Table 2 and Figure 1. Values for DB test, 
30:15 ratio and Valsalva ratio had decreased at T16 compared to recruitment at baseline (T0), in 
both study groups (Figure 1a, b, c). On univariate analysis, at T16, the Ab-positive patients had 
lower DB test values compared to Ab-negative patients (p < 0.05) but the difference was no longer 
significant after adjusting for HbA1c, diabetes duration and baseline DB value by linear regression 
(p = 0.081) (Figure 1a). Similarly, the 30:15 ratio and Valsalva ratio mean values were lower in the 
Ab-positive patients, although not significantly, compared to the Ab-negative patients. Using 
dichotomised data, Ab-positive patients had more abnormal tests (at least 1 abnormal test in 13/19, 
68%; >1 abnormal test in 8/19, 42%) than Ab-negative patients (at least 1 abnormal test in 15/47, 
32%; >1 abnormal test in 4/47, 8%), p < 0.005 and p < 0.002, respectively (Table 2). 
Seven patients (11%) reported autonomic symptoms at cardiovascular, gastrointestinal, 
genitourinary or sudomotor level (Table 2). Postural systolic blood pressure drop > 20 mmHg upon 
standing was detected in 2 patients, while another 5 reported occasional orthostatic symptoms 
(fainting feeling) with an average systolic blood pressure drop of -11mmHg. Presence of autonomic 
symptoms was associated with positivity for either anti-vagus nerve Ab or anti-cervical ganglia Ab 
(5/19, 26%) compared to Ab-negative patients (2/47, 4%) (p < 0.05) (Table 2). The patients who 
reported autonomic symptoms had higher HbA1c values during the previous 5 years (73.4 ± 16 
mmol/mol) than asymptomatic ones (59.9 ± 9 mmol/mol) (p < 0.01). 
Symptoms of peripheral somatic neuropathy were reported by 12 patients (18%) at the feet 
or hands (Table 2). Carpal tunnel syndrome was diagnosed in 4 of them by electrophysiological 
assessment. One patient had developed multiple sclerosis. There was a trend to higher prevalence of 
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symptoms among patients with depressed reflexes (5/19, 26%) compared to those with evocable 
reflexes (7/47, 15%). Vibratory perception threshold was higher in the patients with depressed 
reflexes (7.5 ± 3.2 V vs 5.2 ± 1.4 V; p < 0.02), and correlated with HbA1c levels over the previous 
5 years (r = 0.27, p < 0.05). Vibratory perception threshold tended to be higher in the patients with 
(6.2 ± 1.9 V) than without (5.6 ± 1.6 V) somatic symptoms, but the difference was not significant. 
Presence of somatic neuropathy did not differ according to Ab status and autonomic function. There 
was no association between neurological variables and presence of microvascular complications or 
smoking habit.  
According to logistic regression analysis, the relative risk for Ab-positive patients of having 
at least one abnormal CV test at T16 was 5.77 [95% CI 1.56-21.33], and that of having an abnormal 
DB test was 14.65 [2.48-86.46]. This effect was independent from HbA1c, which was 
independently responsible for the increase of the relative risk for an altered CV test (RR: 1.06 [95% 
CI 1.002-1.13] per mmol/mol HbA1c increase) (Table 3). 
 
Progression of neuropathy 
Prevalence of at least one abnormal/borderline CV test significantly increased from 5% at 
T0, to 12% (25%) at T4, without significant differences between Ab-positive and Ab-negative 
patients (11, 12), to 42% at T16 (p <0.05 vs T0 and T4), with higher prevalence among the Ab-
positive (p < 0.005 vs Ab-negative) (Table 2). Prevalence of autonomic symptoms, which were not 
detected at T0 and T4, was also higher at T16 (p < 0.05). A postural pressure drop >20 mmHg 
consistently persisted at follow-up in 2 patients. 
The presence of Abs to autonomic nervous structures at T0 carried over a 68% probability 
for development of one altered CV test at T16, while the absence of Abs at T0 carried a 91% 
probability of not having an abnormal DB test and an 89% probability of not having an altered 
Valsalva ratio at T16. 
The prevalence of somatic symptoms, not detected at T0, increased from 14% (13/92) at T4, 
to 18% (12/66) at T16, and the prevalence of impaired reflexes from 6% (5/85) at T0, to 16% 
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(15/92) at T4 to 29% (19/66) at T16 (p < 0.05 vs T0). Four patients consistently showed absent or 
depressed ankle reflexes, and 4 were still complaining of somatic symptoms since T4.  
 
Quality of life 
The total DQOL score was lower (better QoL) in men (72.68 ± 12.2) than women (84.70 ± 
20.1) (p < 0.001). Presence of autonomic symptoms was associated with a higher (worse) score 
(94.3 ± 25.8) than in the patients without symptoms (75.4 ± 15.4) (p < 0.001).  
With reference to the 4 subscales explored, Satisfaction did not significantly correlate with any of 
the explored clinical variables. Impact was better in men (29.6 ± 5.9) than women (34.1 ± 6.7) 
(p=0.011), and associated with symptoms of autonomic neuropathy (36 ± 10.4 vs 30.9 ± 5.8) 
(p=0.008). Social/Vocational Worries was also better in men (9.0 ± 2.1 vs 11.4 ± 6.4) (p=0.03), and 
worse in patients with autonomic symptoms (14.8 ± 7.4 vs 9.3 ± 3.5) (p=0.01). The score for 
Diabetes-Related Worries was again better in men (6.3 ± 1.2 vs 8.5 ± 3.3), p < 0.001, and worse in 
presence of autonomic symptoms (9.3 ± 4.7 vs 6.9 ± 2.1) (p = 0.023).  
A higher score for Diabetes-Related Worries was associated with past occurrence of severe 
hypoglycaemia (8.6 ± 4.3 vs 6.8 ± 1.5) (p = 0.014). 
There were no correlations between the scores of the DQOL, or any of its subscales, and the 
presence and severity of somatic neuropathy or retinopathy. 
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Discussion 
The pathogenic mechanisms underlying diabetic peripheral polyneuropathies are multiple, 
interrelated and, possibly, mutually perpetuating. Several lines of research indicate that immune 
determinants are likely to be involved in the events culminating in autonomic nerve damage, within 
the constellation of autoimmune stigmata that characterise type 1 diabetes (7-10, 21). The 
association, however, awaits confirmation. The present prospective study, conducted in young 
patients without established autonomic neuropathy at recruitment and followed for over 16 years 
until adulthood, strongly indicates that a cause-effect relationship may exist between autoantibodies 
to autonomic nervous tissues and development of diabetic autonomic neuropathy. Incipient or 
established CAN (22) reached a prevalence of 68% among the Ab-positive patients, significantly 
higher compared to the Ab-negative patients. The heart rate response to deep breathing, mainly 
mediated by the parasympathetic nervous system, was the most impaired CV test in the time course 
analysis, possibly reflecting early parasympathetic damage. Logistic regression analysis indicates 
that autoantibodies carry an almost 15-fold increased relative risk of developing an abnormal DB 
test over 16 years and an almost 6-fold increase of developing at least one abnormal CV test, 
independent of other variables.  
Previous studies showed that, once present, autoantibodies to autonomic nervous structures persist 
(12, 13) and were consistently detected in our patients at recruitment and 4 years later. The 
proportion of autoantibody-positives was similar to that reported in adult patients with established 
diabetic autonomic neuropathy (7-10). While in our previous reports on this cohort we could not 
detect a clear association with CAN, this longer follow-up study highlights a significant association. 
This suggests that autoimmune mechanisms targeting sympathetic and parasympathetic structures 
may play a primary aetiological role in the development and progression of autonomic dysfunction 
in type 1 diabetes in the long term. Indeed, positivity for autoantibodies had a high positive 
predictive value for the later development of autonomic neuropathy. 
Our study is in line with the only other prospective study detecting a relative risk of 7.5 to 
develop at least one abnormal autonomic test amongst Ab positive patients over a period of 13-14 
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years, unrelated to glycaemic control (13). In addition, in line with others (6, 23, 24), our study 
indicates that autonomic abnormalities also have an independent relationship with glycaemic 
control. In fact, multivariate regression analysis showed that previous long term glycaemic control 
was the only other determinant for increased relative risk of altered CV tests. In this series, diabetes 
duration appeared to be a minor predictor of CAN, in contrast to other reports (25).  
A multi-step process can be envisaged in which nerve damage is first initiated by vascular, 
metabolic and/or autoimmune mechanisms, and perpetuated/amplified by the same autoimmune 
mechanisms, as neuronal autoantigens are released. Autoimmunity is evoked to explain the 
pathogenesis of idiopathic and paraneoplastic dysautonomic syndromes, with levels of 
autoantibodies targeting ganglionic acetylcholine receptors (AchR) correlating with the severity of 
autonomic dysfunction (14, 26, 27). Those studies indicate a potential therapeutic role for 
acetylcholinesterase inhibitors in the enhancement of autonomic function (15). Circulating 
autoantibodies to autonomic nervous structures and subclinical autonomic neuropathy are present in 
other autoimmune disorders, such as rheumatoid arthritis and lupus (28). In type 1 diabetes, the 
target autoantigens within the vagus nerve and cervical ganglia have not been identified. They 
might include the ganglionic neurotransmission and the smooth muscle calcium channels (29). 
Intriguingly, borderline levels of ganglionic AChR antibodies were detected in a patient with both 
celiac disease and type 1 diabetes and one patient with celiac disease and subclinical neuropathy 
(30). Furthermore, in the context of autoimmune diabetes, there is evidence for predominant active 
B-cell response in situ against pancreatic nervous system elements (31, 32), suggesting a shared 
propensity for β cell and neuronal tissue autoimmunity. 
 Diabetic autonomic neuropathy, possibly the least recognised and most overlooked of 
diabetic complications, has increasingly gained attention as an independent predictor of silent 
myocardial ischemia and mortality, as consistently indicated by several cross sectional studies (2, 3, 
33). The pooled prevalence rate risk for silent ischemia is estimated at 1.96 by meta-analysis studies 
(5). In this report, established CAN (22) was detected in near 20% of young adult patients with 
acceptable metabolic control, after over approximately 23 years of diabetes duration, against 12% 
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of patients of the same cohort with subtle asymptomatic autonomic dysfunction (one abnormal CV 
test) a decade earlier, in line with other studies in type 1 diabetes (2, 24). Approximately 30% of the 
patients, developed signs of peripheral somatic neuropathy, not associated with autonomic 
dysfunction. This discrepancy suggests the participation of pathogenic mechanisms different from 
metabolic control and a distinct clinical course, as indicated by the DCCT study, where 
hyperglycaemia had a less robust relationship with autonomic than somatic neuropathy (6). 
Furthermore, symptoms at different levels of the autonomic system, which were previously absent, 
appeared in 10% of patients at T16. In line with the analysis of the risk determinants, autonomic 
symptoms were associated both with the presence of autoantibodies and a worse glycaemic control. 
Orthostatic hypotension was the earliest documented symptom in the course of this longitudinal 
survey (12). However, it was only detected at follow up in the two patients with altered CV tests 
and impaired quality of life. The data suggest that early detection of autonomic derangement might 
be susceptible to correction by appropriate intervention, at least in its functional if not organic 
component (34). Similarly to what happened with the slowly evolving history of islet cell 
autommunity, identification of target antigens within nervous tissue will probably allow the setting 
of specific immunometric assays, overcoming the limits of immunofluorescence techniques. 
However, the assay employed in this paper is both feasible and reproducible (11-13) and it is hoped 
that demonstration of its predictive value will stimulate both the development of more specific 
techniques and more systematic search for autonomic neuropathy in the patients. 
Furthermore, this study shows that autonomic neuropathy, together with female sex and the 
occurrence of severe hypoglycaemias, is a major determinant for poor quality of life in patients with 
type 1 diabetes. This is in agreement with previous reports (35), and linked to such invalidating 
symptoms as orthostatic hypotension and chronic diarrhoea. In fact, the subscales involved were 
Impact of diabetes, Social/Vocational Worries and Diabetes-Related Worries. In contrast, somatic 
neuropathy, not associated with impaired QoL in this cohort, was mostly present as non-painful 
paraesthesias, whereas previous reports of impaired QoL were in people with painful neuropathy or 
detected by the more specific NeuroQoL (36), which we did not use because a validated Italian 
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version is not available for this questionnaire. Previous reports had shown better quality of life 
among men than women, both in general and diabetic populations (37, 38) and a relationship 
between quality of life and hypoglycaemia was also reported by others (35, 38). In this cohort, the 
impact of severe hypoglycaemia was specifically related to the Diabetes-Related Worries subscale.  
In conclusion, the present study provides persuasive evidence for a primary pathogenic role of 
autoimmunity in the development of autonomic diabetic neuropathy. However, the mechanisms 
through which autoantibodies impair their target organ function, whether through classical 
complement action, pro-apoptotic effects of complement, enhanced antigen presentation or 
channelopathy (26, 39, 40), remain to be elucidated. 
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Table 1. Clinical characteristics of the diabetic patients at T16 screening. 
 Diabetic patients at 
T16 
n = 66 
Nervous tissue Ab 
positive patients 
n = 19 
Nervous tissue Ab 
negative patients 
n = 47 
Age (years  SD) (range) 
M : F 
31.4 ± 2 (28-36) 
33 : 33 
31.3 ± 2 (28-36) 
9 : 10 
31.5 ± 2 (28-35) 
24 : 23 
Duration of diabetes (years  SD) (range) 23.4 ± 3.7 (16-31) 22.6 ± 3.2 (16-28) 23.6 ± 3.8 (16-31) 
Follow-up duration (years  SD) 16.5 ± 1.2 16.2 ± 1.4 16.6 ± 1.1 
HbA1c % (mmol/mol)*   Previous year 
                                          Previous 5 years 
7.81 ± 1.14 (61 ± 12) 
7.8 ± 1 (62 ± 11) 
8 ± 0.8 (64 ± 9) 
7.9 ± 0.7 (63 ± 8) 
7.7 ± 1.3 (61 ± 14) 
7.8 ± 1.2 (61 ± 13) 
Insulin (U/Kg) 0.73 ± 0.17 0.70 ± 0.15 0.74 ± 0.18 
Microalbuminuria 7 (11%) 3 (16%) 4 (9%) 
Background retinopathy 
Laser-treatment 
37 (54%) 
7 (11%) 
12 (63%) 
2 (11%) 
25 (53%) 
5 (11%) 
Smoke habit 
Ex-smokers 
21 (32%) 
5 (7%) 
4 (21%) 
1 (5%) 
17 (36%) 
4 (9%) 
Hypo/Hyperthyroidism 8 / 1 5 / 0 3 / 1 
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Coeliac disease 4 3 1 
Hypertension 4 (6%) 0 4 (9%) 
Anti-vagus nerve Ab positive 
Anti-cervical ganglia Ab positive 
Both Ab positive 
8 (12%) 
10 (15%) 
1 
8 
10 
1 
- 
- 
- 
Data are n (%) or means ± SD  
*HbA1c levels refer to values of the previous year (mean of 3 values) and the previous 5 years (mean of available data) 
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Table 2. Abnormal cardiovascular tests, reflex examination and somatic or autonomic symptoms, 
according to the status of autoantibodies to autonomic nervous tissues.  
 
 
 
Patients at T16 
n=66 
Nervous tissue Ab 
positive patients 
n=19 
Nervous tissue Ab 
negative patients 
n=47 
Resting heart rate (bpm) 77 ± 12 79 ± 11 76 ± 13 
 
Normal CV test 38 (%) 
 
6 (%) 32 (%) 
Abnormal/borderline CV tests 
                                        One CV test 
                                        Two CV tests 
                                        Three CV tests 
                                         Four CV tests 
28 (42%) 
 
16 
 
13 (68%)* 
 
5 
 
15 (32%) 
 
11 
 
10 
 
7 3 
 
1 
 
1 0 
1 0 1 
Autonomic symptoms 
        Postural pressure drop >20 mmHg 
        Gastrointestinal symptoms 
        Genitourinary symptoms 
         Sudomotor symptoms 
7 (11%) 
 
2 
5 (26%)† 
 
1 
2 (4%) 
 
1§ 
 
2 
 
1 
 
1 
 
2 
 
1 
 
1 
 
3 
 
2 
 
1 
Absent or depressed reflexes  
Persistently depressed since T4 
19 (29%) 
4 
5 (26%) 
1 
14 (30%) 
3 
Somatic symptoms 
Symptoms persistent since T4 
12 (18%) 
4 
4 (21%) 
1 
8 (17/%) 
3 
Data are n (%) or means ± SD  
* p = 0.05 vs Ab negative patients, both for one and more then one abnormal test (DB test abnormal 
in 8/13, 30:15 ratio abnormal in 6/13, Valsalva ratio abnormal in 7/13) 
† p = 0.05 vs Ab negative patients 
§ The same patient reported postural hypotension, gastrointestinal and genitourinary symptoms 
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Table 3. Multivariate logistic regression analysis testing the independent effect of the Ab presence 
on altered CV tests, adjusted for gender, disease duration and HbA1c level.  
 β coefficient RR 
(95% CI) 
p value 
AT LEAST ONE ALTERED CV TEST AT T16 
Sex  -0.239 0.788 
(0.227-2.729) 
0.707 
Disease duration 0.132 1.141 
(0.964-1.351) 
0.125 
5 years HbA1c 0.062 1.064 
(1.002-1.13) 
0.04 
Ab presence  1.752 5.77 
(1.56-21.33) 
0.009 
ALTERED DB TEST AT T16 
Sex -0.960 
 
0.383 
(0.072-2.033) 
0.26 
Disease duration 0.199 1.22 
(0.955-1.56) 
0.112 
5 years HbA1c 0.097 1.102 
(1.021-1.19) 
0.013 
Ab presence 2.685 14.65 
(2.48-86.46) 
0.003 
DB at T0 -.098 0.907 
(0.808-1.018) 
0.097 
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Figure legends. 
Figure 1. Results of cardiovascular tests. Mean ± SD value of DB test (A), 30:15 ratio (B) and 
Valsalva ratio (C), in Ab negative (open circle) and Ab positive (close circle) patients. T0 
recruitment, T4 at 4 year follow-up, and T16 at 16 year follow-up. 
* p < 0.05 compared to values at T0 for both study groups. 
§ p < 0.05 compared to values in Ab negative patients. 
 
 
